Literature DB >> 3289605

A comparative study of combination chemotherapy versus marrow transplant in first remission in adult acute lymphoblastic leukaemia.

S J Proctor1, P J Hamilton, P Taylor, P Carey, S Hargrave, R G Evans, G Summerfield, R Finney, P Saunders, D Goff.   

Abstract

The results of conventional chemotherapy in adult acute lymphoblastic leukaemia (ALL) have not improved substantially in recent years. The present study is based on a flexible policy of marrow transplantation (allograft and autograft without marrow purging) in first remission compared with a group treated with standard maintenance therapy after a common induction sequence. The actuarial disease free survival (DFS) and actuarial overall survival (OS) at 3 years for autologous marrow grafted patients was 30% and 65% respectively. The allogeneic transplant group had DFS of 30% and OS at 3 years of 38% compared with DFS (12%) and OS (12%) for patients on 6-mercaptopurine and methotrexate maintenance. The actuarial disease free survival calculations include patients on protocol not entering remission, therefore, giving the worst possible result. We conclude that high dose chemo/radiotherapy with autologous marrow rescue in first remission followed by no maintenance provides better results in terms of overall survival and quality of life than standard ALL maintenance in adult patients. Results for allogeneic transplant in ALL are less good in terms of duration and quality of survival and the majority of deaths are related to causes other than leukaemic relapse.

Entities:  

Mesh:

Year:  1988        PMID: 3289605     DOI: 10.1111/j.1365-2141.1988.tb07599.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

Review 1.  Autotransplants with peripheral blood stem cells and clinical results obtained in children: a review.

Authors:  K Leibundgut; A Hirt; A R Lüthy; A Tobler; H P Wagner
Journal:  Eur J Pediatr       Date:  1993-07       Impact factor: 3.183

Review 2.  Autologous bone marrow and peripheral blood stem cell transplantation in haematological malignancies: current status.

Authors:  G Marcoullis; J Mehta; J Treleaven
Journal:  Med Oncol       Date:  1995-12       Impact factor: 3.064

3.  Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region Lymphoma Group.

Authors:  P R Taylor; G H Jackson; A L Lennard; H Lucraft; S J Proctor
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

4.  Autologous bone marrow transplantation in poor-risk high-grade non-Hodgkin's lymphoma in first complete remission. Newcastle and Northern Lymphoma Group.

Authors:  G H Jackson; A L Lennard; P R Taylor; P Carey; B Angus; H Lucraft; R G Evans; S J Proctor
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.